267 related articles for article (PubMed ID: 11751380)
1. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer.
Park DJ; Stoehlmacher J; Zhang W; Tsao-Wei DD; Groshen S; Lenz HJ
Cancer Res; 2001 Dec; 61(24):8654-8. PubMed ID: 11751380
[TBL] [Abstract][Full Text] [Related]
2. [Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Sun Y; Xu BH; Lin DX
Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):972-5. PubMed ID: 16061005
[TBL] [Abstract][Full Text] [Related]
3. Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer.
Gao WM; Romkes M; Day RD; Siegfried JM; Luketich JD; Mady HH; Melhem MF; Keohavong P
Carcinogenesis; 2003 Oct; 24(10):1671-6. PubMed ID: 12844488
[TBL] [Abstract][Full Text] [Related]
4. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.
Park DJ; Zhang W; Stoehlmacher J; Tsao-Wei D; Groshen S; Gil J; Yun J; Sones E; Mallik N; Lenz HJ
Clin Adv Hematol Oncol; 2003 Mar; 1(3):162-6. PubMed ID: 16224397
[TBL] [Abstract][Full Text] [Related]
5. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.
Gurubhagavatula S; Liu G; Park S; Zhou W; Su L; Wain JC; Lynch TJ; Neuberg DS; Christiani DC
J Clin Oncol; 2004 Jul; 22(13):2594-601. PubMed ID: 15173214
[TBL] [Abstract][Full Text] [Related]
6. XPD codon 751 polymorphism, metabolism genes, smoking, and bladder cancer risk.
Stern MC; Johnson LR; Bell DA; Taylor JA
Cancer Epidemiol Biomarkers Prev; 2002 Oct; 11(10 Pt 1):1004-11. PubMed ID: 12376500
[TBL] [Abstract][Full Text] [Related]
7. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
Ryu JS; Hong YC; Han HS; Lee JE; Kim S; Park YM; Kim YC; Hwang TS
Lung Cancer; 2004 Jun; 44(3):311-6. PubMed ID: 15140544
[TBL] [Abstract][Full Text] [Related]
8. [Relationship between single nucleotide polymorphism in repair gene XPD751 and prognosis in colorectal carcinoma patients].
Chen YM; Wu XL; Zhang LW; Xu X; Liu JW
Zhonghua Zhong Liu Za Zhi; 2012 Jul; 34(7):501-5. PubMed ID: 22967467
[TBL] [Abstract][Full Text] [Related]
9. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
Liang J; Jiang T; Yao RY; Liu ZM; Lv HY; Qi WW
Cancer Chemother Pharmacol; 2010 Aug; 66(3):493-500. PubMed ID: 19960344
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.
Ruzzo A; Graziano F; Loupakis F; Rulli E; Canestrari E; Santini D; Catalano V; Ficarelli R; Maltese P; Bisonni R; Masi G; Schiavon G; Giordani P; Giustini L; Falcone A; Tonini G; Silva R; Mattioli R; Floriani I; Magnani M
J Clin Oncol; 2007 Apr; 25(10):1247-54. PubMed ID: 17401013
[TBL] [Abstract][Full Text] [Related]
11. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.
Giachino DF; Ghio P; Regazzoni S; Mandrile G; Novello S; Selvaggi G; Gregori D; DeMarchi M; Scagliotti GV
Clin Cancer Res; 2007 May; 13(10):2876-81. PubMed ID: 17504986
[TBL] [Abstract][Full Text] [Related]
12. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.
Viguier J; Boige V; Miquel C; Pocard M; Giraudeau B; Sabourin JC; Ducreux M; Sarasin A; Praz F
Clin Cancer Res; 2005 Sep; 11(17):6212-7. PubMed ID: 16144923
[TBL] [Abstract][Full Text] [Related]
13. Gene-environment interaction for the ERCC2 polymorphisms and cumulative cigarette smoking exposure in lung cancer.
Zhou W; Liu G; Miller DP; Thurston SW; Xu LL; Wain JC; Lynch TJ; Su L; Christiani DC
Cancer Res; 2002 Mar; 62(5):1377-81. PubMed ID: 11888908
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in XPD exons 10 and 23 and bladder cancer risk.
Schabath MB; Delclos GL; Grossman HB; Wang Y; Lerner SP; Chamberlain RM; Spitz MR; Wu X
Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):878-84. PubMed ID: 15824159
[TBL] [Abstract][Full Text] [Related]
15. Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer.
Booton R; Ward T; Heighway J; Taylor P; Power F; Ashcroft L; Morris J; Thatcher N
Cancer; 2006 Jun; 106(11):2421-7. PubMed ID: 16649224
[TBL] [Abstract][Full Text] [Related]
16. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms in the DNA repair gene XPD and susceptibility to esophageal squamous cell carcinoma.
Yu HP; Wang XL; Sun X; Su YH; Wang YJ; Lu B; Shi LY; Xiong CL; Li YY; Li F; Xu SQ
Cancer Genet Cytogenet; 2004 Oct; 154(1):10-5. PubMed ID: 15381366
[TBL] [Abstract][Full Text] [Related]
18. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.
Liu D; O'Day SJ; Yang D; Boasberg P; Milford R; Kristedja T; Groshen S; Weber J
Clin Cancer Res; 2005 Feb; 11(3):1237-46. PubMed ID: 15709194
[TBL] [Abstract][Full Text] [Related]
19. XRCC1 and XPD polymorphisms and esophageal adenocarcinoma risk.
Liu G; Zhou W; Yeap BY; Su L; Wain JC; Poneros JM; Nishioka NS; Lynch TJ; Christiani DC
Carcinogenesis; 2007 Jun; 28(6):1254-8. PubMed ID: 17264068
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms of the DNA repair genes XRCC1, XRCC3, XPD, interaction with environmental exposures, and bladder cancer risk in a case-control study in northern Italy.
Shen M; Hung RJ; Brennan P; Malaveille C; Donato F; Placidi D; Carta A; Hautefeuille A; Boffetta P; Porru S
Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1234-40. PubMed ID: 14652287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
